30.68

1.41% -0.44

Viridian Therapeutics Inc (VRDN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Viridian Therapeutics Inc stock is traded at $30.68, with a volume of 1.06M. It is down -1.41% in the last 24 hours and up +0.82% over the past month. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Previous Close:

$31.12

Open:

$30.8

24h Volume:

1.06M

Relative Volume:

0.71

Market Cap:

$2.93B

Revenue:

$305.00K

Net Income/Loss:

$-328.98M

P/E Ratio:

-7.1931

EPS:

-4.2652

Net Cash Flow:

$-309.60M

1W Performance:

-3.76%

1M Performance:

+0.82%

6M Performance:

+101.44%

1Y Performance:

+55.26%

1-Day Range:

$30.35

$31.54

1-Week Range:

$30.35

$31.89

52-Week Range:

$9.90

$34.04

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name

Viridian Therapeutics Inc

Sector

Healthcare (1131)

Industry

Biotechnology (631)

Phone

617.272.4600

Address

221 CRESCENT STREET, WALTHAM

Employee

143

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

VRDN's Discussions on Twitter

Compare VRDN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRDN Viridian Therapeutics Inc	30.68	2.97B	305.00K	-328.98M	-309.60M	-4.2652
VRTX Vertex Pharmaceuticals Inc	452.13	115.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.31	81.12B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.17	52.54B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	839.99	51.78B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.12	37.12B	447.02M	-1.18B	-906.14M	-6.1812

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-25	Reiterated	Wedbush	Outperform
Dec-03-25	Initiated	William Blair	Outperform
Nov-24-25	Initiated	Truist	Buy
Aug-25-25	Resumed	Jefferies	Buy
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-25-24	Initiated	TD Cowen	Buy
Sep-11-24	Reiterated	Needham	Buy
Jun-11-24	Initiated	Wolfe Research	Outperform
Jun-06-24	Initiated	Goldman	Buy
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jun-14-23	Initiated	BTIG Research	Buy
Jun-14-23	Resumed	Credit Suisse	Outperform
May-30-23	Initiated	RBC Capital Mkts	Outperform
Apr-17-23	Initiated	Wells Fargo	Overweight
Mar-30-23	Initiated	Stifel	Buy
Dec-19-22	Initiated	Cowen	Outperform
Dec-19-22	Initiated	Needham	Buy
Dec-16-22	Initiated	Credit Suisse	Outperform
Dec-01-22	Initiated	H.C. Wainwright	Buy
Jun-23-22	Initiated	B. Riley Securities	Buy
Nov-18-21	Initiated	SVB Leerink	Outperform
Oct-12-21	Initiated	Evercore ISI	Outperform
Jan-25-21	Initiated	Ladenburg Thalmann	Buy

View All

Viridian Therapeutics Inc Stock (VRDN) Latest News

Jan 02, 2026

Viridian Therapeutics (NASDAQ:VRDN) Insider Sells $70,795.52 in Stock - MarketBeat

Jan 02, 2026

Insider Sell: Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics Inc (VRDN) - GuruFocus

Jan 02, 2026

What analysts say about Viridian Therapeutics Inc stockGrowth vs. Value Investing & Low Risk Investment Tips - earlytimes.in

Jan 02, 2026

Dec 31, 2025

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga

Dec 31, 2025

Dec 30, 2025

Simplify Asset Management Inc. Purchases Shares of 50,000 Viridian Therapeutics, Inc. $VRDN - MarketBeat

Dec 30, 2025

Dec 29, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Dec 29, 2025

Dec 27, 2025

Market Fear: How Viridian Therapeutics Inc 1S1 stock performs during market turbulenceJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - moha.gov.vn

Dec 27, 2025

Rice Hall James & Associates LLC Purchases 336,040 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat

Dec 27, 2025

Dec 24, 2025

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail

Dec 24, 2025

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Sanofi (OtherSNYNF) - The Globe and Mail

Dec 24, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK) - The Globe and Mail

Dec 24, 2025

Dec 23, 2025

VRDN: Needham Maintains Buy Rating and Raises Price Target | VRD - GuruFocus

Dec 23, 2025

Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $42.00 at Needham & Company LLC - MarketBeat

Dec 23, 2025

Viridian Therapeutics: De-Risked Veligrotug Program and Compelling Phase III Data Support Undervalued Buy Rating - TipRanks

Dec 23, 2025

Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN) - The Globe and Mail

Dec 23, 2025

Dec 22, 2025

Viridian Therapeutics Says FDA Accepts Biologics License Application for Veligrotug - marketscreener.com

Dec 22, 2025

Viridian Therapeutics (VRDN) Gains FDA Priority Review for Thyro - GuruFocus

Dec 22, 2025

Viridian Therapeutics announces BLA acceptance and Priority Review for Veligrotug for the treatment of thyroid eye disease - marketscreener.com

Dec 22, 2025

Viridian Therapeutics Announces BLA Acceptance And Priority Review For Veligrotug For The Treatment Of Thyroid Eye Disease - TradingView — Track All Markets

Dec 22, 2025

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease - Business Wire

Dec 22, 2025

Dec 20, 2025

Will Viridian Therapeutics Inc. stock attract more institutional investorsJuly 2025 Retail & High Win Rate Trade Tips - Улправда

Dec 20, 2025

Published on: 2025-12-20 23:42:03 - Улправда

Dec 20, 2025

Will Viridian Therapeutics Inc. stock deliver consistent dividendsGlobal Markets & Weekly High Return Stock Forecasts - ulpravda.ru

Dec 20, 2025

FDA Review Of Veli For Thyroid Eye Disease Might Change The Case For Investing In Viridian Therapeutics (VRDN) - Sahm

Dec 20, 2025

Dec 19, 2025

Aug Action: How geopolitical tensions affect Viridian Therapeutics Inc. stock2025 Support & Resistance & Community Verified Trade Signals - Улправда

Dec 19, 2025

Will Viridian Therapeutics Inc. stock outperform international peersJuly 2025 Update & Stepwise Trade Signal Implementation - Улправда

Dec 19, 2025

Why Viridian Therapeutics Inc. (1S1) stock gets analyst attentionMarket Trend Summary & Weekly Breakout Watchlists - DonanımHaber

Dec 19, 2025

Published on: 2025-12-19 16:37:51 - Улправда

Dec 19, 2025

Evercore ISI Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail

Dec 19, 2025

Dec 18, 2025

Fed Watch: Will Viridian Therapeutics Inc. stock attract more institutional investorsPortfolio Update Report & AI Powered Buy and Sell Recommendations - Улправда

Dec 18, 2025

Goldman Sachs reiterates Buy rating on Viridian Therapeutic stock By Investing.com - Investing.com Canada

Dec 18, 2025

Will Viridian Therapeutics Inc. stock continue upward momentumJuly 2025 Trends & Smart Money Movement Alerts - Улправда

Dec 18, 2025

Dec 17, 2025

Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Viridian Therapeutics (VRDN) and OmniAb (OABI) - The Globe and Mail

Dec 17, 2025

Dec 16, 2025

Viridian Therapeutics stock reaches 52-week high at 33.67 USD - Investing.com India

Dec 16, 2025

Dec 15, 2025